Technology ID

Exo-Clean Technology for Purifying Extracellular Vesicle Preparations from Contaminants

Lead Inventor
Jones, Jennifer (NCI)
Berzofsky, Jay (NCI)
Welsh, Joshua (NCI)
McKinnon, Katherine (NCI)
Research Materials
Therapeutic Areas
Development Stages
Lead IC

Extracellular Vesicles (EVs), including exosomes and microvesicles, are nanometer-sized membranous vesicles that can carry different types of cargos, such as proteins, nucleic acids and metabolites. EVs are produced and released by most cell types. They act as biological mediators for intercellular communication via delivery of their cargos. This unique ability spurred translational research interest for targeted delivery of therapeutic molecules to treat a wide range of diseases. EVs also contain interesting information of their specific cellular origin. Thus, EVs can reveal nature, severity, and prognosis of a various pathophysiologic disease states. Such characteristics also make them a reliable and stable source of biomarkers, accessible in several body fluids. However, their small size makes it difficult to isolate EVs by using standard purification methods commonly used for isolating cells and platelets. Currently available techniques for EV isolation, are non-scalable, labor intensive, time consuming, and ineffective in removing contaminants.

Researchers at the National Cancer Institute (NCI) developed a chromatographic EV purification technology using a custom-made “mixed mode” resin. The resin combines Capto Core-type resin with other affinity-based beads for depletion of unwanted contaminants smaller than 700 MDa – such as proteins, nucleic acids, or other molecules. This Exo-Clean technology is both broadly applicable for biofluid processing and scalable for high-throughput screening (i.e., compatible with robotic 96- or 384- well format). This technology is also suitable for large-scale GMP production of therapeutic exosome and other EV analogue-based therapeutics. 

Unique biophysical features of this technology could offer a new avenue for developing EV based clinical biomarkers, and therapeutics. The NCI seeks commercial partners to co-develop and/or license this technology.

Competitive Advantages:

  • Efficient in removing proteins and various labels from EV preparations
  • Scalable for high-throughput screening
  • Amenable to a wide range of preparation scales and formats


Commercial Applications:

  • Research tool for studying structure and function of EVs
  • EV-based clinical biomarkers for detecting various pathological conditions
  • Therapeutic exosome and other EV analogue-based therapeutics for targeted drug delivery


Licensing Contact:
Patterson, Wendy